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Abstract Introduction: Mounting evidence suggests an important role for the intestinal
microbiota in the chronic mucosal inflammation that occurs in inflammatory
bowel disease (IBD), and novel molecular approaches have further identified a
dysbiosis in these patients. Several mechanisms of action of probiotic products
thatmay interfere with possible aetiological factors in IBDhave been postulated.
Objective: Our objective was to discuss the rationale for probiotics in IBD
and to systematically review clinical intervention studies with probiotics in
the management of IBD in adults.
Methods: A systematic search was performed in PubMed up to 1 October
2011, using defined keywords. Only full-text papers in the English language
addressing clinical outcomes in adult patients were included. The 41 eligible
studies were categorized on disease type (ulcerative colitis [UC] with/without
an ileo-anal pouch and Crohn’s disease [CD]) and disease activity. Pooled
odds ratios were only calculated per probiotic for a specific patient group
when more than one randomized controlled trial was available.
Results: Well designed randomized controlled trials supporting the applica-
tion of probiotics in the management of IBD are still limited. Meta-analyses
could only be performed for a limited number of studies revealing overall risk
ratios of 2.70 (95% CI 0.47, 15.33) for inducing remission in active UC with
Bifido-fermented milk versus placebo or no additive treatment (n = 2); 1.88
(95% CI 0.96, 3.67) for inducing remission in active UC with VSL#3 versus
placebo (n = 2); 1.08 (95% CI 0.86, 1.37) for preventing relapses in inactive
UCwithEscherichia coliNissle 1917 versus standard treatment (n= 3); 0.17 (95%
CI 0.09, 0.33) for preventing relapses in inactiveUC/ileo-anal pouch anastomosis
(IPAA) patients with VSL#3 versus placebo; 1.21 (95% CI 0.57, 2.57) for pre-
venting endoscopic recurrences in inactive CDwith Lactobacillus rhamnosusGG
versus placebo (n= 2); and 0.93 (95% CI 0.63, 1.38) for preventing endoscopic
recurrences in inactive CD with Lactobacillus johnsonii versus placebo (n= 2).
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Conclusion: Further well designed studies based on intention-to-treat analy-
ses by several independent research groups are still warranted to support
the promising results for E. coli Nissle in inactive UC and the multispecies
product VSL#3 in active UC and inactive pouch patients. So far, no evidence
is available to support the use of probiotics in CD. Future studies should
focus on specific disease subtypes and disease location. Further insight into
the aetiology of IBD and the mechanisms of probiotic strains will aid in
selecting probiotic strains for specific disease entities and disease locations.
1. Introduction
The recent introduction of phylogenetic mo-
lecular approaches targeting the small subunit
(SSU) ribosomal RNA gene of bacteria has re-
sulted in a major breakthrough in knowledge on
the composition of the intestinal microbiota. This
complex ecosystem develops after birth, when
our sterile gastrointestinal tract (GIT) becomes
rapidly colonized by successive waves of micro-
organisms until a dense microbial population,
comprising 1013–14 bacteria and hundreds of dif-
ferent species, stabilizes at about time of weaning.
The density and diversity increases from the stom-
ach towards the colon. The individual faecal mi-
crobiota has been found to be relatively stable
over time, but differs between subjects.[1,2] Despite
the high inter-individual diversity, the human gut
microbiota is dominated by the phyla Firmicutes
and Bacteroidetes[2-4] and contains a core micro-
biome with shared functionality.[5] A recent pub-
lication in Nature[6] revealed that the intestinal
microbial composition of humans segregates into
three distinct clusters, designated as ‘enterotypes’.
Independent of ethnic background, gender, age
and body mass index (BMI), the intestinal mi-
crobiota of each individual can be mapped to one
of these three ecosystems. These enterotypes are
driven by enrichment of the genera Bacteroides,
Prevotella and Ruminococcus, respectively. Fur-
thermore, this study demonstrated that abundant
molecular functions were not necessarily pro-
vided by abundant species, indicating that both
compositional and functional analyses of the in-
testinal microbiota are important.
Lessons from germ-free animals illustrate that
commensal micro-organisms are necessary for
the development and maturation of the intestinal
immune system and the epithelium.[7] Further-
more, the intestinal microbiota contributes to the
defence against pathogens by the mechanism of
colonization resistance and has a high metabolic
activity. Saccharolytic bacterial fermentation of
non-digestible carbohydrates, occurring mostly
in the proximal colon, is especially important
because of the production of short-chain fatty
acids (SCFAs, i.e. acetate, propionate and buty-
rate). Butyrate is a major energy source for in-
testinal epithelial cells, affects cell proliferation,
differentiation, mucus secretion and barrier func-
tion, and has anti-inflammatory and anti-oxidative
potential.[8]
The intestinal microbiota is increasingly rec-
ognized as involved in a wide range of not only
gastrointestinal but also systemic disease entities,
including inflammatory bowel disease (IBD), ir-
ritable bowel syndrome (IBS), obesity and the
metabolic syndrome.[9,10] In the present review
we address the role of the intestinal microbiota
and the rationale for interventions with probiotics
in IBD. A systematic overview is performed of
clinical intervention studies with probiotics for
the management of IBD in adults.
2. The Intestinal Microbiota in
Inflammatory Bowel Disease (IBD)
IBD is a group of chronic relapsing inflamma-
tory disorders of the GIT and primarily com-
prises ulcerative colitis (UC) and Crohn’s disease
(CD). In the US, approximately 1.5million peo-
ple suffer from IBD. The incidences vary between
6 and 8 per 100 000 for CD and between 9 and 12
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per 100 000 for UC.[11] IBD is an invalidating dis-
ease with a peak onset in subjects between 15 and
30 years of age. Ethnic and familial clustering
suggested a genetic background of IBD that was
confirmed with the identification of the first CD
gene CARD15.[12,13] However, geographic varia-
tion and the worldwide increase in incidence in
line with Western lifestyles, as well as migration
studies, also indicate that environmental factors
may play a major role.[11,14,15] IBD is generally
acknowledged to have a complex multi-factorial
aetiology that results in a heterogenic clinical
presentation. Although UC and CD are both char-
acterized by the clinical symptoms abdominal
pain, diarrhoea, rectal bleeding and weight loss,
they are different pathological entities, both with
various disease phenotypes. UC is characterized
by continuous superficial mucosal inflammation
restricted to the colon, spreading out from the
distal part. CD is most frequent in the ileum and
the colon, but can affect any part of the GIT. The
inflammation is discontinuous, and often trans-
mural, and therefore CD can be complicated by
strictures and fistulas. Furthermore, CD is asso-
ciated with intestinal granulomas, which are not
typical for UC. Extra-intestinal disease manifes-
tations of the skin, the liver, the eyes or the joints
are present in up to 40% of CD and UC patients.
The first evidence for a role of the intestinal
microbiota in IBD came from a variety of animal
colitis models, which did not develop inflamma-
tion when raised under germ-free conditions.[15]
In IBD patients, the relevance of intestinal bac-
teria is supported by findings that intestinal in-
flammation is often present in anatomical areas
with high bacterial numbers,[16,17] the mucosal
bacterial counts are higher in IBD patients than in
healthy controls[17,18] and diversion of the faecal
stream proximal to the inflamed mucosa resulted
in a decreased disease activity in CD patients.[19-22]
Furthermore, a recent meta-analysis, including ten
and nine randomized controlled trials (RCTs),
showed a significant benefit of antibiotic over pla-
cebo treatment for inducing remission in CD (risk
ratio [RR] 0.85, 95% CI 0.73, 0.99) and UC (RR
0.64, 95% CI 0.43, 0.96), respectively.[23]
Apart from inconsistent findings on the aetio-
logical role of Mycobacterium paratuberculosis,
Listeria monocytogenis and paramyxoviruses,[24]
no specific micro-organism has yet been identi-
fied as a possible causal factor, but a dysbiosis of
the commensal intestinal microbiota has been
reported in IBD. Using, for example, fluorescent
in situ hybridization (FISH), quantitative poly-
merase chain reaction (PCR) and pyrosequencing
approaches, the faecal microbiota was found to
be less diverse[25-27] and to have a different com-
position in IBD compared with controls as well as
in UC versus CD patients.[4,28,29] Also in mucosal
specimens, the diversitywas found to be lower,[4,30,31]
but total bacterial numbers were increased[32,33]
and the overall composition was different in IBD
compared with controls.[4,30,31] In general, fewer
Firmicutes were found,[28,34,35] as well as a re-
duced diversity within this phylum.[3] Low bac-
terial counts of Faecalibacterium prausnitzii, a
major representative of the Clostridium leptum
group within the phylum Firmicutes, were found
to be associated with active IBD[36] and with
CD,[29] which is of interest because of its butyrate-
generating and anti-inflammatory capacity. The
diversity of the Bacteroidetes phylum was also
found to be reduced in IBD,[3] but data on their
bacterial counts were inconsistent.[29,34,35] Fur-
thermore, less bifidobacteria[37-39] and an in-
crease of Enterobacteraceae, especially increased
numbers of adherent Escherichia coli, are dem-
onstrated by several groups.[35,39,40] With regard
to the metabolic activity of the intestinal mi-
crobiota, decreased faecal concentrations of bu-
tyrate have been reported in UC,[4,41] and a
significant decrease of the transcriptional activity
of the mucosa-associated microbiota has been
found in both IBD groups compared with healthy
volunteers.[34]
A few groups studied the intestinal microbiota
in relation to disease activity. Although not con-
firmed in all studies, different bacterial numbers
were found comparing active with inactive UC
or CD patients.[29,36,39] A different composition
and less diversity was also found comparing in-
flamed with non-inflamed mucosal samples
within patients,[29,35,42] but so far no bacterial
species or clusters have been identified as asso-
ciated with inflammatory status. In line with
the heterogeneity in disease phenotypes, both the
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faecal- and mucosa-associated microbiota have
been found to differ between subjects with ileal
versus colon predominant CD.[25,43] This obser-
vation was recently confirmed by Frank et al.,[30]
who further found an altered microbiota com-
position by disease genotype based on the pres-
ence of NOD2 and/or ATG16L1 gene mutations.
2.1 Loss of Oral Tolerance to
Commensal Bacteria
Apart from a dysbiosis, patients with IBD are
characterized by an exaggerated response to com-
mensal bacteria, which is thought to be an impor-
tant factor driving the intestinal inflammation.
Although the exact mechanisms involved in loss
of oral tolerance in IBD remain enigmatic, an
increased mucosal infiltration of activated CD4+
lymphocytes, dysfunctional dendritic cells, dys-
regulated macrophage-induced immune responses
and abnormalities in regulatory pathways have
been demonstrated.[44,45] The subsets of CD4+
T cells involved in either UC or CD seem to be dif-
ferent. In CD, an increased production of T helper
(Th)-1 cytokines and the Th17 cytokine interleu-
kin (IL)-17 has been observed,[7,45,46] whereas inUC
patients, a preferential expression of Th2 cyto-
kines IL-4 and IL-5 as well as an increase in IL-17
has been reported.[44,45,47] Reduced numbers of
regulatory T cells, producing the anti-inflammatory
cytokines IL-10 and/or transforming growth factor
(TGF)-b, are found in both UC and CD.[7,44] Host
defense against commensal bacteria could be
further diminished by an aberrant expression of
or response to Toll-like receptors (TLR);[45,48,49] a
decreased production of antimicrobial peptides,
mucous and secretory immunoglubulin A (sIgA);
deficiencies in inflammasomes being sensors of
damage-associated molecular patterns leading to
inflammation and apoptosis and a disruption of
intercellular tight junctions as found in (sub-
groups of) IBD patients.[44,50,51]
The genetic susceptibility observed in IBD will
contribute to the loss of oral tolerance. Genome-
wide association studies have identified 99 sus-
ceptibility loci, of which 71 are associated with
CD, 47 with UC and 28 with both CD andUC.[52]
Many of them encode proteins involved in innate
or adaptive immunity. Genes involved in IL-10
signalling and in the IL-23/Th17 pathway are ex-
amples of associations with both UC and
CD,[13,52] whereas mutations in the intracellular
pattern recognition NOD2/CARD15 and in the
autophagy genes ATG16L1 and IRGM are asso-
ciated with an increased risk of developing
CD.[13,44] These associations can further differ
between disease phenotypes, as Wehkamp and
colleagues[53,54] found decreased messenger RNA
(mRNA) levels of human a-defensin 5 in CD
patients with ileal disease, which were associated
with the presence of mutations in theNOD2 gene.
3. Rationale for Probiotics in IBD
Both UC and CD are associated with a signif-
icant burden for patients as well as for the health-
care system. Treatment is based onmedical therapy
and surgical interventions. In the US, approxi-
mately one-third of the estimated $US63 billion
for IBD-associated costs are spent on medica-
tion.[11,55] For induction of remission or main-
tenance, 5-aminosalicylic acid (5-ASA) drugs,
corticosteroids, budesonide, thiopurines, metho-
trexate and tumour necrosis factor (TNF)-a
blocking agents are used. They are associated
with a wide range of possible severe side effects,
such as leukopenia, liver function abnormalities,
interstitial nephritis and pancreatitis.[11,55] With
the exception of mesalazine, all the drugs used
reach their effect by non-specific suppression of
the immune system and therefore patients can
develop (opportunistic) infections. Furthermore,
an increased risk of developing lymphomas has
been suggested for thiopurines and TNFa
blocking agents.[56,57] Therapeutic interventions
addressing possible causative factors, such as mi-
crobial dysbiosis, in the initiation or progression
of IBD could therefore be of additive value.
Although the exact aetiology is not yet clear,
the generally accepted hypothesis suggests that
IBD arises from loss of oral tolerance to the com-
mensal microbiota, resulting in chronic intestinal
inflammation in genetically predisposed hosts.
Although a detailed characterization of the in-
testinal microbiota in IBD is not yet available,
many studies, as discussed in section 2, have dem-
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onstrated differences in its composition in UC
and CD compared with controls, as well as within
both patient groups in relation to disease activity,
location and genotype. Whether the observed
changes are a cause or a consequence of the in-
flammation still has to be further elucidated.
Nevertheless, manipulation of the indigenous in-
testinal microbiota composition and activity, the
immune system and host barrier function, is the
main rationale for intervention studies with pro-
biotics in IBD.
Probiotics are defined as ‘‘live microorganisms,
which when administered in adequate amounts
confer a health benefit to the host.’’[58] They should
be of human origin, genetically stable and able to
survive passage through the GIT (i.e. low pH, bile
and digestive enzymes). Furthermore, theymust be
safe, and postulated health effects must be proven
in human intervention studies. Apart from single
bacterial strains, such as Lactobacillus spp. or
Bifidobacterium spp., multispecies products are
increasingly applied. As different bacterial strains
can have different effects, they may act com-
plementarily or even synergistically.[59]
Several possible mechanisms of probiotics
may contribute to a health effect in IBD. Pro-
biotic bacteria may affect the composition of the
microbial ecosystem by competition for nutrients
and adhesion sites, by the production of anti-
microbial substances and/or via cell-cell commu-
nication.[60,61] Furthermore, they may affect the
host immune system by interaction of bacterial
products, cell wall components or DNA with
epithelial and gut-associated immune cells.[62]
Subsequently, changes in cytokine production,
modulation of dendritic cell function, increased
natural killer cell activity and the induction of
regulatory T cells and defensins have been demon-
strated.[60,62,63] Finally, probiotics can contribute to
the production of SCFAs (e.g. butyrate) or affect
the intestinal barrier function by induction of
mucin secretion, enhancement of tight-junction
expression and functioning and reduction of epi-
thelial cell apoptosis.[64-67] These mechanisms
of action have mainly been studied in vitro,
ex vivo or in animal studies, and it has to be ac-
knowledged that effects are found to differ be-
tween probiotic strains.
First lessons on probiotics reducing chronic
intestinal inflammation came from animal stud-
ies.[68] In IBD patients, most studies have focused
on maintaining or inducing remission. The next
sections provide a critical review of the available
literature on probiotic intervention studies for the
management of IBD, addressing clinical outcome
parameters in adult patients.
4. Methods of Literature Review
A systematic search was conducted in PubMed
up to 1 October 2011, using the following (trun-
cated) keywords ‘IBD, inflammatory bowel dis-
ease*, ulcerative, colitis, Crohn* or pouch*’ in
any combination with ‘probiotic*, lactobacill* or
bifidobact*’. The search was limited to full-text
English written papers, resulting in 1421 hits. By
screening the titles and abstracts, studies perform-
ed in vitro, in animals, among minors (<18 years
of age), reviews and studies on prebiotics or syn-
biotics were subsequently excluded. Full text of
the remaining 58 papers on probiotics in adult
IBD patients was checked. Only those investi-
gating clinical outcome, either as a primary or
secondary outcome parameter, in adult IBD
patients were considered eligible for evaluation.
Clinical outcome was defined by (validated)
clinical activity indices and endoscopic and/or
histological scores. One additional paper was
found by checking references of pertinent articles.
Studies analysing subgroups of previously pub-
lished trials were not included for the evaluation
of clinical outcome to avoid over-representation,
but will be discussed in case of mechanistic sup-
port. Finally, 43 studies were included in this
systematic review. As aetiological factors and
clinical presentation differs between IBD entities
and phenotypes, studies investigating active (n= 13)
or inactive UC (n = 8), CD patients (n = 8) or UC
patients with an ileo-anal pouch anastomosis
(IPAA) [n = 12] were discussed separately. The
studies by Karimi et al.[69] and Lorea Baroja
et al.[70] investigated IBD patients as one group
(including both UC and CD), and were therefore
not included in the further analyses (figure 1).
The methodological quality for each of the
included studies was assessed using the following
Probiotics and Inflammatory Bowel Disease 807
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components: presence or absence of a randomized
controlled design; double blinding; intention-to-
treat (ITT) analysis; and compliance check. Quality
indicators not reported were considered to be ab-
sent. The information on methodological quality is
available as Supplemental Digital Content, avail-
able at URL: http://links.adisonline.com/DGZ/A9.
Information on probiotic strains used, dose and
duration of treatment is included in the subgroup-
specific tables for active UC, inactive UC, UC
with an ileo-anal pouch and CD patients, respec-
tively (tables I–IV).
4.1 Meta-Analyses
Subgroup-specific meta-analyses were only
performed per probiotic, when more than one
RCT addressing remission or relapse rate were
available for a specific patient group. For each
of the included studies, RRs and their 95% con-
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outcome or analysing 
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published trials
Studies included in qualitative synthesis (n = 43):
-  active UC (n = 13)
-  inactive UC (n = 8)
-  UC IPAA (n = 12)
-  CD (n = 8)
-  combination UC and CD (n = 2)
Studies included in quantitative synthesis
(meta-analysis) [n = 15]:
-  active UC/Bifido-fermented milk (n = 2)
-  active UC/VSL#3 (n = 3)
-  inactive UC IPAA/Escherichia coli Nissle 1917
   (n = 3)
-  inactive UC IPAA/VSL#3 (n = 3)
-  inactive CD/Lactobacillus rhamnosus GG (n = 2)
-  inactive CD/Lactobacillus johnsonii (n = 2)
Fig. 1. Study selection process. CD =Crohn’s disease; IPAA = ileo-anal pouch anastomosis; UC = ulcerative colitis.
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Table I. Probiotic intervention studies in adult ulcerative colitis patients with active disease
Study, y of
publication
Number of pts, disease
activity
Design, duration Intervention (daily dosea) Clinical outcome
Guslandi et al.,[71]
2003
25, mild to moderately
active
Uncontrolled, 4wk Saccharomyces boulardii
(750mg) +mesalazine (3 g)













(10· 109) vs no additive tx
Relapse rate: 27% vs 90% (ITT
p =0.0075)




20, moderately active RCT vs PL, 12wk Bifido-fermented milk [B. breve, B.
bifidum and L. acidophilus]
(10· 109) vs PL
40% vs 33% in remission (PP)
Decreased clinical activity







90, moderately active RCT vs standard
tx, 8wk
VSL#3 (9· 1011)+ balsalazide
(2.25 g) vs balsalazide (4.5 g) vs
mesalazine (2.4 g)
80% vs 77% vs 53.3% in
remission (ITT p< 0.02)
Faster remission induction: 4 vs
7.5 vs 13d (p <0.01)
Bibiloni et al.,[75]
2005
34, moderately active Uncontrolled, 6wk VSL#3 (3.6 · 1012) 53% entered remission (ITT)
77% decreased ‡3 points in
clinical activity index (ITT)
Tsuda et al.,[76]
2007
20, mild to moderately
refractory active
Uncontrolled, 4wk BIO-THREE (Streptococcus
faecalis 18mg, Clostridium
butyricum 90mg, Bacillus
mesentericus 90mg) [n =10: also
100 g dietary fibre daily]





Uncontrolled, 5wk VSL#3 (1.8 · 1012) Decrease in clinical disease







67% reached remission (ITT)
Sood et al.,[79]
2009
147, mild to moderately
active
RCT vs PL, 12wk VSL#3 (3.6 · 1012) vs PL ‡50% improved disease activity
at wk 6 in 32.5% vs 10% (ITT
p =0.001)
Remission at wk 12: 42.9% vs
15.7% (ITT p <0.001)
Matthes et al.,[80]
2010
90, mild to moderately
active
RCT vs PL, 8wk Escherichia coliNissle 1917 enema
(4· 109) vs (2· 109) vs (109) vs PL
Remission rates:
43.5% vs 47.8% vs 36.4% vs
35.0% (ITT p =0.4430)
52.9% vs 44.4% vs 27.3% vs
18.2% (PP p =0.0446)
Tursi et al.,[81]
2010
144, mild to moderately
active
RCT vs PL, 8wk VSL#3 (3.6 · 1012) vs PL More subjects with ‡50%
improvement in disease activity
(PP p= 0.010, ITT p= 0.031)
Remission rates 47.7% vs







Case report Bifidobacterium spp. (6mg), 1wk Improved physical
condition/colonoscopic score
Continued next page
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fidence intervals were calculated based upon the
reported rates of relapses or maintenance of re-
mission. Unless stated otherwise, rates of remis-
sion or relapses were based on ITT analyses.
To derive a pooled RR (RRpooled) from in-
dividual studies, we used a random-effects meta-
analysis model. Heterogeneity was quantified
with the I-square index, which describes the pro-
portion of total variation in study estimates due
to heterogeneity.[112]
Statistical analyses were conducted using the
‘metan’ commandwithin Stata version 11 (STATA
Corp, College Station, TX, USA). The results were
displayed as Forest Plots.
5. Results
5.1 Ulcerative Colitis (UC) Patients with
Active Disease
Bennet et al.[113] were the first to treat a patient
with active UC with antibiotics and a single rectal
enema of the faecal microbiota of a healthy donor,
and successfully induced remission for at least
6 months. A similar approach was published by
Borody et al.[114] Subsequently, several probiotic
intervention studies have been performed in ac-
tive UC, with large variations in probiotic strains
used, dose, duration and study designs (table I).
Parts of these studies have also been reviewed by
others.[115]
A case report[82] and single uncontrolled
trials[71,76,78] were not considered sufficient to
substantiate a beneficial effect of the probiotics
studied.
Two randomized placebo-controlled trials
were performed with Bifido-fermented-milk con-
taining Bifidobacterium breve strain Yakult,
Bifidobacterium bifidum and Lactobacillus acid-
ophilus in mild to moderately active UC
patients.[72,73] Ishikawa et al.[72] found signif-
icantly fewer relapses in the probiotic versus the
control group without additive treatment after
12 months’ treatment (n = 21), as well as a signifi-
cant decrease of the Bacteroides vulgatus – total
Bacteroides ratio and decrease of butyrate within
the probiotic group. No further changes in culture-
based microbial analyses and faecal SCFAs were
found. Kato et al.[73] found a significant decrease
of clinical activity in the probiotic versus the pla-
cebo group after 12 weeks’ treatment (n = 20), but
did not find differences in relapse rate.[73] The
RRpooled was 2.70 (95% CI 0.47, 15.33), indicat-
ing that, overall, no significant benefit was found
for Bifido-fermented milk in inducing remission
in active UC patients (figure 2a).
A randomized, placebo-controlled, phase II
dose-finding study was performed with E. coli
Nissle 1917 in 90 patients with mild to moderately
active UC.[80] They were the first to administer
the probiotics rectally to increase the local action.
Clinical remission rates showed a significant
dose-dependent higher responder rate than pla-
cebo in the per-protocol (PP) but not in the ITT
analysis. The latter was probably due to the high
number of drop-outs because of protocol viola-
tions and discontinuation because of lack of
efficacy. The number of side effects did not differ
between groups. D’Inca et al.[83] compared orally
or rectally administered Lactobacillus casei DG
in combination with 5-ASA versus 5-ASA alone
for 8 weeks in 26 patients with mildly active UC.
The histological activity scores improved signifi-




Number of pts, disease
activity
Design, duration Intervention (daily dosea) Clinical outcome
D’Inca et al.,[83]
2011
26, mild active RCT vs standard
tx, 8wk
5-ASA (2.4 g) vs
5-ASA +Lactobacillus casei
(1.6 · 109) orally vs 5-ASA +
L. casei (1.6 · 109) rectally
Improved clinical activity in
5-ASA group (ITT p= 0.043)
Improved histology in both
L. casei groups (ITT p< 0.05)
a Daily dose provided in CFU unless stated otherwise.
5-ASA =5-aminosalicylic acid; CFU = colony-forming units; ITT = intention-to-treat analysis; PL =placebo; PP =per protocol analysis;
pts = patients; RCT = randomized controlled trial; tx = treatment; UC = ulcerative colitis.
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ings were supported by changes in the microbiota
and TLR-expression, but the subgroups were
very small, and the clinical activity scored only
improved significantly within the 5-ASA group.
The effect of VSL#3 consisting of four strains of
Lactobacillus (L. casei, L. plantarum, L. acidophilus
and L. delbrueckii subsp. bulgaricus), three strains of
Bifidobacterium (B. longum, B. breve and B. infantis)
and one strain of Streptococcus (S. salivarius subsp.
thermophilus), has been investigated in two un-
controlled and three randomized controlled
studies. The uncontrolled studies reported clin-
ical remission in 53% of 34 patients with moder-
ately active UC[75] and a significant decrease in
clinical activity index[77] in a mixed group of
patients with active and inactive UC (n = 15) after
treatment with VSL#3. In a randomized, con-
trolled, three-arm study including 90 patients
with moderately active UC, Tursi et al.[74] com-
pared the combination of VSL#3 with balsalazide
versus balsalazide or mesalazine alone for 8 weeks
and found significantly more patients entering
clinical remission based on ITT analysis, as well as a
faster induction of remission. Two other large, well
designed, randomized, placebo-controlled trials
found significantly more patients with mild to
moderately active UC to reach at least 50% im-
provement in clinical activity indices after VSL#3
compared with placebo treatment for 12 (n= 147)[79]
and 8 weeks (n = 144)[81] based on ITT analyses.
In both studies, concomitant medication was
continued in a stable dose. In contrast to the
findings by Sood et al.,[79] the study by Tursi
et al.,[81] which had a relatively high placebo re-
sponse, could not find significant differences in
remission rates. Major side effects did not occur
in any of the studies using VSL#3. Further sup-
portive mechanistic data mainly result from
animal colitis models, showing an increase of lu-
minal microbial diversity,[116] inhibition of pro-
Table II. Probiotic intervention studies in adult patients with ulcerative colitis in remission
Study, y of
publication
Number of pts, disease
activity
Design, duration Intervention (daily dosea) Clinical outcome
Kruis et al.,[84]
1997
103, inactive RCT vs standard
tx, 12wk
Escherichia coli Nissle 1917
(50 ·109) vs mesalazine
(3 ·500mg)
Similar relapse rate:
16.0% vs 11.3% (ITT, NS)







E. coli Nissle 1917 (50 ·109) vs
mesalazine (3 ·400mg)













30, inactive after inducing
remission
RCT vs PL, 8wk Bifid triple viable capsule (1.26 g)
vs PL




327, inactive RCT vs standard
tx, 12mo
E. coliNissle 1917 (2–50 · 109) vs
mesalazine (3 ·500mg)
Similar relapse rate
45.1 vs 37.0% (ITT p = 0.013)
36.4% vs 33.9% (PP p =0.003)
Zocco et al.,[89]
2006
187, inactive RCT vs standard
tx, 12mo
Lactobacillus rhamnosus GG
(18 ·109) vs mesalazine
(2400mg) vs L. GG
(18 ·109) +mesalazine
(2400mg)
Similar relapse rate: 15% vs
20% vs 16% (ITT p= 0.77)










(500mg) + rifaximin (400mg)




32, inactive RCT vs PL, 52wk Lactobacillus acidophilus (La-
5) +Bifidobacterium animalis
lactis [Bb-12] (1.5 · 1011) vs PL
Maintenance remission 25% vs
8% (ITT p = 0.37)
a Daily dose provided in CFU unless stated otherwise.
5-ASA =5-aminosalicylic acid; CFU = colony-forming units; ITT = intention-to-treat analysis; NS =not significant; PL = placebo; PP =per
protocol analysis; pts = patients; RCT = randomized controlled trial; tx = treatment.
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inflammatory cytokines, induction of IL-10 and
regulatory CD4+ T cells,[117] as well as an increased
expression of tight junction proteins and a decrease
of apoptosis[118] after treatment with VSL#3.
A meta-analysis was performed including the
two studies comparing VSL#3 versus place-
bo[79,81] and the one by Tursi et al.[74] comparing
the combination of VSL#3 with balsalazide ver-
sus mesalazine. The subsequent RRpooled was
1.69 (95% CI 1.17, 2.43), indicating a significant
benefit of VSL#3 over control in inducing remis-
sion in patients with active UC (figure 2b).
However, I2 indicates a moderate heterogeneity
between the studies. The study by Tursi et al.[74]
compared the combination of VSL#3 with bal-
salazide versus standard maintenance therapy,
while the others compared VSL#3 versus placebo.
After exclusion of the study by Tursi et al.,[74] a
similar trend was found, but the RRpooled was not
found to be significant (1.88, 95% CI 0.96, 3.67).
Table III. Probiotic intervention studies in adult ulcerative colitis patients with an ileo-anal pouch anastomosis
Study, y of publication Number of pts,
disease activity




2, active pouchitis Uncontrolled,
315/56d
Escherichia coli Nissle 1917
(2.5–5 ·1010)




23, mild to active
pouchitis
Uncontrolled, 4wk VSL#3 (36 ·1011) 69% in remission (ITT)











20, with history of
pouchitis (subgroup
had pouchitis)
RCT vs PL, 3mo Lactobacillus rhamnosus GG
(2–4· 1010) vs PL






RCT vs PL, 12mo VSL#3 (9 ·1011) vs PL 10% vs 40% relapses (p < 0.05)
Increased PDAI in PL (p <0.001)
but not VSL#3 group
Laake et al.,[97]
2003
10, in remission Uncontrolled, 4wk Lactobacillus acidophilus
(La-5) +Bifidobacterium
lactis [Bb-12] (5· 1010)
Significant change in endoscopic
but not histological scores
Laake et al.,[98]
2004
41, in remission Uncontrolled, 4wk L. acidophilus (La-5) +
B. lactis [Bb-12] (both 5 ·1010)
22 completers
Increased PDAI but not
histological scores (PP p =0.01)
Mimura et al.,[99]
2004
36, in remission after
4wk antibiotics







group without tx, 3 y
L. rhamnosus GG (1.4 · 1010)
vs no tx







Uncontrolled, 4wk L. acidophilus (La-5)+B. lactis
[Bb-12] (both 5· 1010) [n = 11
used dietary fibre preparation]
Improved endoscopic PDAI
(p= 0.0001)








Uncontrolled, 8mo VSL#3 (18 ·1011) 25 stopped, 6 completers
Improved clinical PDAI (PP




31, in remission RCT vs no tx,
12mo
VSL#3 (9 ·1011) or no tx 28 completed the study
Decreased PDAI within VSL#3
group (PP p< 0.01)
a Daily dose provided in CFU unless stated otherwise.
CFU = colony-forming units; IPAA = ileo-anal pouch anastomosis; ITT = intention-to-treat analysis; NS =not significant; PDAI =Pouch Disease
Activity Index; PL =placebo; PP =per protocol analysis; pts =patients; (R)CT = (randomized) controlled trial; tx = treatment.
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5.2 UC Patients with Inactive Disease
Eight studies were identified that investigated
probiotics in patients with inactive UC (table II).
Two of them comprised single uncontrolled studies
with Saccharomyces boulardii[90] and VSL#3,[86]
respectively, and no conclusions can be drawn
from them.
Three large, randomized, controlled, double-
dummy trials compared E. coli Nissle 1917 with
mesalazine (1200–1500mg). They found similar
relapse rates in both groups after 12 weeks[84] or
12 months[85,88] of intervention, based on ITT
analyses. Furthermore, no differences were ob-
served in side effects between the groups. The
authors concluded that the E. coli Nissle was
equally effective as mesalazine for maintaining
remission. The findings were supported by
animal studies, in whichE. coliNissle did result in
a significant improvement of acute dextran-
sulfate sodium-induced colitis. This was paralleled
by a decrease of pro-inflammatory cytokines, in
Table IV. Probiotic intervention studies in adult patients with Crohn’s disease
Study, y of
publication
Numbers of pts, disease
activity, disease location




23, active, all colon RCT vs PL, 12mo Prednisolon + Escherichia
coli Nissle 1917 (5· 1010) vs
prednisolon+PL
75% vs 91.7% entered
remission (ITT NS)

















subsp. thermophilus (8 ·109)
Maintained remission but 1wk
abdominal pain (after 7 and




32, inactive, 9 ileum,




(1 g)+mesalazine (2 g) vs
mesalazine (3 g)




45 inactive (10 d after
curative resection),
35 ileum, 3 colon,
7 ileum + colon
RCT vs PL, 12mo Lactobacillus rhamnosus GG
(12 ·109) vs PL
Clinical relapse in 16.6% vs
10.5% (PP p =0.948)
60% vs 35.3% of those in
remission had endoscopic
recurrence (PP p = 0.297)
Marteau et al.,[109]
2006
98, after curative resection,
54 ileum, 4 colon,
40 ileum + colon
RCT vs PL, 6mo Lactobacillus johnsonii LA1
(4 ·109) vs PL
90 pts evaluated
Similar recurrence rate: 49% vs
64% (ITT p = 0.15)




9, entering remission after
steroids + antibiotics,
disease location unknown
RCT vs PL, 6mo L. rhamnosus GG (2· 109)
vs PL
2 of 4 vs 3 of 5 relapsed (ITT)
Van Gossum
et al.,[111] 2007
70, after curative ileo-
caecal resection
RCT vs PL, 12wk L. johnsonii (1010) vs PL Endoscopic recurrence rate is
71 vs 63% (PP)
No differences in endoscopic
score or recurrence rate (ITT
and PP)
a Daily dose provided in CFU unless stated otherwise.
CFU = colony-forming units; ITT = intention-to-treat analysis; NR =not reported; NS =not significant; PP= per protocol analysis; RCT =
randomized controlled trial.
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part mediated by TLRs[119,120] and by a regula-
tion of the tight junction protein ZO-1 with a
reduction of the intestinal permeability.[67] The
RRpooled was 1.08 (95% CI 0.86, 1.37), indicating
that E. coliNissle was not statistically significantly
inferior to mesalazine in preventing relapses (i.e. or
maintaining remission) [figure 3a].
In a large RCT including 187 patients,[89]
Lactobacillus rhamnosus strain GG with or with-
out mesalazine resulted in relapse rates and clin-
ical, endoscopic and histological scores similar to
those of mesalazine only. They did not have drop-
outs, nor did severe side effects occur. Possible
mechanisms of actions were not assessed. In
contrast, in a murine DSS model L. rhamnosus
GG was found to aggregate colitis.[121]
Two placebo-controlled studies were pub-
lished.[87,91] Cui et al.[87] studied 30 patients with
inactive UC who were randomized to receive the
multispecies probiotic ‘bifido triple viable cap-
sule’ or placebo for 8 weeks. Significantly fewer
relapses were found in the probiotic versus the
placebo group, together with changes in the com-
position of the faecal microbiota, inhibition of
mucosal nuclear factor (NF)-kB activation, de-
creases of TNFa and IL-1b and an increase of IL-
10 tissue mRNA levels.[87] The beneficial effect in
this single small study should be confirmed in large
RCTs and is hampered by missing information on
bacterial strains and numbers administered.
Wildt et al.[91] performed a randomized placebo-
controlled trial comparing UC patients in remis-
sion treated with the multispecies Probio-Tec Ab
25 (containing L. acidophilus La-5 plus Bifido-
bacterium animalis subsp. lactis Bb-12) [n = 20]
versus placebo (n = 12) for 52 weeks, but found no
differences in maintenance of remission or in
median time to relapses between both groups.
5.3 UC Patients with an Ileo-Anal
Pouch Anastomosis
Twelve studies were identified that investigated
the application of probiotics in UC patients with
an IPAA (table III). IPAA is the restorative
































Heterogeneity: Tau2 = 0.96;
Chi2 = 2.46, df = 2 (P = 0.12); l2 = 19%
Heterogeneity: Tau2 = 0.05;
Chi2 = 3.78, df = 2 (p = 0.15); l2 = 47%
Bifido-fermented milk for inducing remission in active UC
Probiotic (n/N) Control (n/N) Weight (%) Risk ratio (95% CI)
41.5
Fig. 2. Probiotics for inducing remission in active ulcerative colitis. Forest plot for comparison of (a) Bifido-fermented milk compared with
placebo or no treatment and (b) VSL#3 compared with placebo in patients with (mild to moderately) active ulcerative colitis. Risk ratio > 1
indicates an increased risk of inducing remission based on intention-to-treat analyses. Ishikawa et al.,[72] Kato et al.,[73] Sood et al.,[79] Tursi
et al.[74,81] UC= ulcerative colitis.
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a surgical resection for therapy-refractory or
corticosteroid-dependent disease. Pouchitis is the
most frequent complication following pouch
surgery. It is characterized by symptoms such as
increased stool frequency and liquidity, abdomi-
nal cramping, urgency, tenesmus and occasion-
ally rectal bleeding or fever and is associated with
inflammation of the pouch mucosa. From a large
study performed at the Mayo Clinic, the cumu-
lative risk for the first episode of pouchitis at 1, 5
and 10 years following IPAA was found to be
15%, 36% and 46%, respectively.[122] Pouchitis is
generally scored by the validated Pouchitis Dis-
ease Activity Index (PDAI), containing clinical,
endoscopic and histological criteria.[123] The
exact aetiology of pouchitis is not clear, but faecal
stasis, mucosal ischaemia, bacterial dysbiosis and
a disturbed immune response are considered to
be involved.[124-126]
Although some studies included mixed patient
groups, only two studies focused on inducing re-
mission in patients with active pouchitis. How-
ever, both suffered from major methodological
limitations, being a case report[92] and an un-
controlled trial.[93]
The most convincing evidence has been found
for the multispecies probiotic VSL#3 in main-
taining remission in IPAApatients. Three random-
ized placebo-controlled studies were performed,
two by Giochetti and colleagues[94,96] and one by
Mimura et al.[99] ITT analyses revealed signif-
icantly lower relapse rates after 9 or 12 months’
intervention in UC patients with a pouch, either
after inducing remission by antibiotics (n = 40
and n = 36)[94,99] or starting 1 week after ileost-
omy closure (n = 40).[96] No side effects were
reported.
In all above-mentioned VSL#3 studies, the
authors demonstrated increased faecal numbers
of S. salivarius, lactobacilli and bifidobacteria,
pointing to survival of the probiotic strains.
Kühbacher et al.[127] performed molecular mi-
crobial analyses in a subgroup of the patients


































Escherichia coli Nissle 1917 for preventing relapses in UC
Probiotic (n/N) Control (n/N) Weight (%) Risk ratio (95% CI)
Heterogeneity: Tau2 = 0.01;
Chi2 = 2.63, df = 2 (P = 0.27); l2 = 24%
Heterogeneity: Tau2 = 0.00;
Chi2 = 0.35, df = 2 (p = 0.84); l2 = 0%
VSL#3 for preventing relapses in UC/IPAA
Fig. 3. Probiotics for preventing relapses in inactive ulcerative colitis/ileo-anal pouch anastomosis. Forest plot for comparison of (a) Es-
cherichia coli Nissle 1917 compared with mesalazine in patients with inactive ulcerative colitis and for (b) VSL#3 compared with placebo in
patients with inactive ulcerative colitis with an ileo-anal pouch anastomosis. Risk ratio > 1 indicates an increased risk of having a relapse based
on intention-to-treat analyses. Kruis et al.,[84,88] Rembacken et al.,[85] Gionchetti et al.,[94,96] Mimura et al.[99] IPAA = ileo-anal pouch anasto-
mosis; UC = ulcerative colitis.
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icant increase of microbial diversity and total
bacterial numbers, and a decrease of fungal di-
versity in biopsy samples of nine pouch patients
in remission treated with VSL#3 for 12 months.
Further mechanistic support was published by
Ulisse et al.[128] and Lammers et al.,[129] who
analysed a subgroup of patients from the study
by Gionchetti et al.[96] A decrease of TNFa, IL-
1a, interferon (IFN)-g cytokine levels, inducible
nitric oxide synthase and matrix metalloprotei-
nase activity and an increase of IL-10 was found
in biopsy samples of seven inactive pouch
patients treated with VSL#3 for 9 months.[128] A
significant decrease was also demonstrated for
mRNA levels of IL-1b, IL-8 and IFNg, as well as
of the numbers of polymorphnuclear cells in tis-
sue samples of eight VSL#3- compared with eight
placebo-treated patients.[129] Finally, Pronio et al.[103]
randomized another 31 pouch patients in remission
to receive VSL#3 or no treatment for 12 months.
They found a significant decrease in PDAI scores
within the probiotic but not in the control group,
paralleled by a significant decrease of tissue IL-1b
mRNA, increase of tissue FOXP3 mRNA and
an increased percentage of mucosal regulatory
T cells in the probiotic versus the placebo group.
The three randomized placebo-controlled
studies[94,96,99] were included in the meta-analysis,
revealing a RRpooled of 0.17 (95% CI 0.09, 0.33)
[figure 3b]. Thereby, VSL#3 was found to be
significantly better than placebo at preventing
relapses in UC patients with an IPAA.
The promising results could not be confirmed
in an uncontrolled clinical practice setting. Shen
et al.[102] treated 31 antibacterial-dependent pou-
chitis patients with a 2-week antibacterial course
to induce remission, and subsequently gave them
VSL#3 for 8 months. They could not find a bene-
ficial effect, and 25 of 31 patients stopped the inter-
vention because of relapses or adverse symptoms.
Another multispecies probiotic, containing
L. acidophilus (La-5) and B. animalis subsp.
lactis (Bb-12), was studied by Laake and col-
leagues[97,98,101] and did result in a significant
improvement in endoscopic and clinical scores in
pouch patients in remission. However, all studies
were uncontrolled and were further hampered by
use of medication for bowel symptoms, use of
dietary fibre and/or incomplete data in subgroups
of patients.
Finally, two studies were published on
L. rhamnosus GG with inconsistent results. A
total of 20 inactive pouch patients with a history
of recurrent pouchitis were randomized to receive
L. rhamnosusGGor placebo for 3 months, but no
significant effect was found on the PDAI.[95]
Gosselink et al.[100] included 117 pouch patients
of whom 39 received L. rhamnosus GG daily
starting after IPAA surgery, and compared them
with a historic ‘untreated’ control group of
78 patients. They found the first episode of pou-
chitis to be less frequent in the L. rhamnosusGG-
treated versus the historic control group after a
3-year follow-up period. However, it has to be
taken into account that a parallel placebo group
was lacking and that surgical and medical inter-
ventions might have improved over time.
5.4 Crohn’s Disease (CD) Patients
Only three small studies have been performed
in patients with active CD (table IV), including
an uncontrolled trial with L. salivarius[130] and a
case report on three CD patients receiving a
multispecies probiotic while on maintenance
therapy.[106] The only placebo-controlled trial, con-
ducted by Malchow,[104] reported a lower relapse
rate after 12 months of follow-up when E. coli
Nissle 1917 was added to prednisolon therapy.
Five studies were performed in inactive CD
patients (table IV). Guslandi et al.[107] studied the
effect of S. boulardii in combination with mesa-
lazine versus mesalazine only in 32 patients with
inactive CD and found a significantly lower re-
lapse rate for the combination. They suggested
that S. boulardii may contribute to this beneficial
effect by its trophic effect on the intestinal mucosa
and increased release of secretory IgA. Further-
more, S. boulardii has been found to improve the
intestinal permeability in CD patients.[131,132] Al-
though no side effects were reported, the beneficial
effect of this single study should be confirmed in
large controlled clinical trials before advice on
routine use can be given.
L. rhamnosus GG was studied in two placebo-
controlled trials that included 45 and 11 patients
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with inactive CD, either directly after curative re-
section or after induction of remission by steroids
and antibiotics, respectively. Both suffered from
rather high drop-out rates and did not find a sig-
nificant benefit of the probiotic over placebo.[108,110]
The effect of Lactobacillus johnsonii was assessed in
two placebo-controlled trials that included 98 and
70 CD patients after curative resection. Neither
study found differences in recurrence rates or en-
doscopic scores.[109,111] Furthermore, in the study by
Van Gossum et al.,[111] the drop-out rate was rather
high (21 out of 70). The RRpooled for L. rhamnosus
GG (1.21, 95%CI 0.57, 2.57) and L. johnsonii (0.93,
95%CI 0.63, 1.38) did confirm the lack of benefit of
probiotic over placebo treatment in preventing re-
lapses in patients with inactive CD (figure 4).
The majority of probiotic intervention studies
in inactive CD did include patients with both ileal
and/or colonic predominant disease and none of
them performed analyses per disease location.
The overall lack of positive results in CD may (in
part) be caused by inter-individual differences
between disease locations (e.g. ileum vs colon) as
well as by differences at the genetic level (e.g.
polymorphisms in NOD2/CARD15).
6. Summary and Conclusion
Mounting evidence suggests an important role
for the intestinal microbiota in the chronic mu-
cosal inflammation in IBD, and novel molecular
approaches have further identified a microbial
dysbiosis in IBD patients. Several mechanisms of
action of probiotic products have been postu-
lated, which may interfere with aetiological fac-
tors in IBD. Therefore, the interest of physicians
and researchers in the application of probiotics in
IBD is increasing. Since several probiotic prod-
ucts are commercially available and marketed as
safe and beneficial for a wide variety of gastro-
intestinal diseases, the usefulness of probiotics is
also a frequently asked question in the consulta-
tion room of IBD clinics.
Lactobacillus rhamnosus GG for preventing relapses in CD
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Risk ratio (95% CI)
1.53 (0.59, 3.97)
0.83 (0.25, 2.80)
1.21 (0.57, 2.57)Heterogeneity: Tau
2 = 0.00;
Chi2 = 0.62, df = 1 (P = 0.43); l2 = 0%
Heterogeneity: Tau2 = 0.04;
Chi2 = 2.18, df = 1 (p = 0.14); l2 = 54%
Fig. 4. Probiotics for preventing relapses in inactive Crohn’s disease. Forest plot for comparison of (a) L. rhamnosus GG versus placebo and
of (b) L. johnsonii compared with placebo in patients with inactive Crohn’s disease. Risk ratio > 1 indicates an increased risk of having a relapse
based on the endoscopic recurrence (per protocol analyses). Prantera et al.,[108] Schultz et al.,[110] Marteau et al.,[109] Van Gossum et al.[111]
CD=Crohn’s disease.
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Based on the current systematic review, level 1
evidence based on well designed randomized
clinical trials and supporting the application of
probiotics in the management of IBD is still lim-
ited. Studies are often not placebo controlled, are
based on small numbers and suffer from high
numbers of drop-outs. The latter stresses the im-
portance of ITT analyses. Furthermore, different
probiotic strains, combination of strains and dos-
ages have been tested. As different strains are
known to evoke different responses, it is generally
acknowledged that results cannot be generalized.
Therefore, meta-analyses were performed per
probiotic applied to a specific patient group and
could only be based on two or three studies per
application.
E. coliNissle 1917 was found to be comparable
to standard treatment in preventing relapses in
inactive UC (RRpooled 1.08, 95% CI 0.86, 1.37).
However, daily dosages of mesalazine were rather
low (1200–1500mg) and results should therefore
be interpreted with care. Most convincing evi-
dence was found for VSL#3 in inducing remission
in patients with mild to moderately active UC
(RRpooled 1.69, 95% CI 1.17, 2.43) and for pre-
venting relapses in inactive UC patients with an
ileo-anal pouch (RRpooled 0.17, 95% CI 0.09,
0.33). The findings were supported by mecha-
nistic data from animal colitis models and pouch
patients. However, moderate heterogeneity was
found for the studies in active UC and the
RRpooled was not significant (1.88, 95% CI 0.96,
3.67) when one study with an active comparator
instead of placebo was left out. The majority of
studies with VSL#3 were performed by the same
research group. Surprisingly, the efficacy of
VSL#3 in pouch patients could not be confirmed
in a clinical setting. This indicates that additional
confirmation of the findings by independent
groups, as well as the investigation of factors in-
terfering with implementation in clinical practice,
is warranted.
In CD, there is not sufficient evidence to sup-
port the use in daily clinical practice of any of the
probiotics tested. As differences are reported in
microbiota composition, defective immune re-
sponses (e.g. human b-defensin expression) and
genetic susceptibility in CD patients with ileum
versus colon involvement, these disease pheno-
types should be studied separately and require a
tailored probiotic selection.
Until now, most definitions of probiotics are
based on ‘live micro-organisms’.[133,134] However,
evidence is growing that non-viable strains, se-
creted metabolites or even DNA-moieties of
probiotic bacteria can also exert a beneficial ef-
fect.[62] Probably, the mechanism of action of a
particular strain in a specific host situation will
determine whether a strain has to be viable. Al-
though clear information on minimal efficacious
(viable) dosages are not available, at least 108–10
colony-forming units per day are generally re-
commended.[58] Differences in dosages used fur-
ther hamper a comparison between studies, and
dose-effect studies are limited. Furthermore,
promising in vitro data will not necessarily lead to
positive results in clinical trials. For an optimal
effect, the probiotic stains have to be able to
adapt to the host environment as well as express
the desired health-promoting effects. The number
of bacteria consumed, as well as matrix of the
product and the bacterial growth phase, will also
affect their efficacy. For an adequate selection of
appropriate probiotic strains or mixtures of
strains, further mechanistic insight on the pro-
biotic-host interaction is warranted for each
application.
Probiotics are considered to be safe because of
their long history of use in food fermentation and
a low overall risk of infections due to lactic acid
bacteria.[135,136] In the studies applying probiotics
in IBD, no major side effects occurred. Most of
the studies allowed concomitant medication in a
stable dose, which is inevitable due to ethical
reasons. However, one has to be careful extra-
polating safety findings of probiotics as ad-
junctive therapy, especially when combined with
immunosuppressive agents or biologicals. A few
case reports have been published on Lactobacillus
spp. causing hepatic abscess and sepsis in IBD
patients.[137,138] Taking into account the increas-
ed mortality in a recent pancreatitis trial after
intraduodenal administration of a multispecies
probiotic,[139] and the limited safety data in
immune-compromised individuals, care must be
taken when using probiotics in severely ill sub-
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jects, especially in those with an impaired in-
testinal barrier function such as patients with
moderate to severe IBD.
In conclusion, further well designed studies
based on ITT analyses by several independent
research groups are still warranted to support the
promising results for E. coliNissle in inactive UC
and for the multispecies product VSL#3 in active
UC and inactive pouch patients. So far, no evi-
dence is available yet to justify the use of probiotics
in CD. Future studies should be designed carefully
and should focus on specific disease subtypes and
disease location. Further insight into the aetiology
of IBD and the biological effects of probiotic
strains will aid in tailored probiotic selection.
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